Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial
Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen).…